Siegfried Holding AG Stock

Equities

SFZN

CH0014284498

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:11 2024-04-19 EDT 5-day change 1st Jan Change
889 CHF +1.37% Intraday chart for Siegfried Holding AG +0.23% +3.43%

Financials

Sales 2024 * 1.3B 1.43B 1.97B Sales 2025 * 1.42B 1.56B 2.15B Capitalization 3.81B 4.19B 5.76B
Net income 2024 * 148M 162M 223M Net income 2025 * 172M 189M 260M EV / Sales 2024 * 3.2 x
Net Debt 2024 * 351M 385M 529M Net Debt 2025 * 313M 344M 473M EV / Sales 2025 * 2.9 x
P/E ratio 2024 *
25.7 x
P/E ratio 2025 *
22.1 x
Employees 3,945
Yield 2024 *
0.43%
Yield 2025 *
0.46%
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.37%
1 week+0.23%
Current month-3.47%
1 month-3.05%
3 months+4.40%
6 months+27.82%
Current year+3.43%
More quotes
1 week
853.00
Extreme 853
899.00
1 month
851.00
Extreme 851
934.00
Current year
827.00
Extreme 827
950.00
1 year
655.00
Extreme 655
950.00
3 years
566.00
Extreme 566
950.00
5 years
313.50
Extreme 313.5
950.00
10 years
136.20
Extreme 136.2
950.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 10-07-31
Director of Finance/CFO 53 17-04-30
Chief Tech/Sci/R&D Officer 56 19-03-31
Members of the board TitleAgeSince
Director/Board Member 55 15-12-31
Director/Board Member 63 13-12-31
Chairman 61 09-12-31
More insiders
Date Price Change Volume
24-04-19 889 +1.37% 4,311
24-04-18 877 -0.11% 5,994
24-04-17 878 -0.90% 3,479
24-04-16 886 -0.45% 4,835
24-04-15 890 +0.34% 3,262

Delayed Quote Swiss Exchange, April 19, 2024 at 11:30 am

More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
889 CHF
Average target price
1,016 CHF
Spread / Average Target
+14.27%
Consensus